Recombinant IL2RA (Daclizumab Biosimilar) antibody

Catalog No. ABIN7487796

Product Details anti-IL2RA (Daclizumab Biosimilar) Antibody

Target: IL2RA (Daclizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Expression System: Mammalian cells

Clonality: Monoclonal

Conjugate: This IL2RA (Daclizumab Biosimilar) antibody is un-conjugated

Application: ELISA

Purpose: Daclizumab Biosimilar - Anti-IL2RA mAb

Characteristics: Antibody Type: IgG1-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Grade: Research Grade

Isotype: IgG1 kappa

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for IL2RA (Daclizumab Biosimilar)

Target: IL2RA (Daclizumab Biosimilar)

Abstract: IL2RA (Daclizumab Biosimilar) Products

Synonyms: CD25 antibody, IDDM10 antibody, IL2R antibody, TCGFR antibody, interleukin 2 receptor subunit alpha antibody, IL2RA antibody

Target Type: Biosimilar

Background: BIIB019,DAC HYP
Daclizumab is a humanized IgG1 monoclonal antibody that binds to human interleukin 2 receptor (anti-Tac or anti-CD25)and composed of human >90%) and murine (10%) antibody sequences. The human sequence is derived from the constant domain of human IgG1 and the variable framework region of Eu myeloma antibody. The murine part was taken from the complementarity-determining regions of a murine anti-Tac antibody. Daclizumab has been used for preventing acute organ rejection in de novo allogeneic kidney transplantation when used simultaneously with immunosuppressive regimens such as cyclosporine and corticosteroid and in the treatment of adult patients with relapsing multiple sclerosis. These trademarks were Zenapax and Zimbryta, respectively.

CAS-No: 152923-56-3